International Agency for Research on Cancer (IARC) - Summaries & Evaluations
VOL.: 21 (1979) (p. 417)
5. Summary of Data Reported and Evaluation
(N.B. - This section should be read in conjunction with the General Remarks on Sex Hormones and with
the General Conclusions on Sex Hormones.)
5.1 Experimental data
Medroxyprogesterone acetate was tested in mice and dogs by
intramuscular administration. It produced mammary tumours in dogs.
Medroxyprogesterone acetate was reported to have teratogenic effects
in some species.
5.2 Human data
One epidemiological study concerning the development of breast nodules
and two studies concerning the development of dysplasias and carcinoma
in situ of the uterine cervix have been reported. The results of these
studies were conflicting and difficult to interpret because of
methodological problems. Epidemiological studies on steroid
hormones used in oestrogen-progestin oral contraceptive preparations have been summarized
in the section, 'Oestrogens and Progestins in Relation to Human Cancer'.
There is limited evidence for the carcinogenicity of
medroxyprogesterone acetate in dogs. Epidemiological studies on
medroxyprogesterone acetate are inadequate for an evaluation of the
carcinogenicity of this compound in humans.
For definition of the italicized terms, see Preamble Evaluation.
Previous evaluation: Vol. 6 (1974)
Subsequent evaluation: Suppl. 7 (1987) (Medroxprogesterone acetate;
Last updated: 7 April 1998